COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

BACKGROUND: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need t...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779784/
https://www.ncbi.nlm.nih.gov/pubmed/35091386
http://dx.doi.org/10.1016/j.jns.2022.120155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8779784/
https://www.ncbi.nlm.nih.gov/pubmed/35091386
http://dx.doi.org/10.1016/j.jns.2022.120155

Ejemplares similares